971 related articles for article (PubMed ID: 17543777)
21. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
22. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
23. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
Delgado JF; Manito N; Segovia J; Almenar L; Arizón JM; Campreciós M; Crespo-Leiro MG; Díaz B; González-Vílchez F; Mirabet S; Palomo J; Roig E; de la Torre JM
Transplant Rev (Orlando); 2009 Apr; 23(2):69-79. PubMed ID: 19298938
[TBL] [Abstract][Full Text] [Related]
24. Malignancies in renal transplantation: an unmet medical need.
Dantal J; Pohanka E
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i4-10. PubMed ID: 17456618
[TBL] [Abstract][Full Text] [Related]
25. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F
Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
[TBL] [Abstract][Full Text] [Related]
26. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
27. The pleiotropic effects of mTor inhibitors.
Ponticelli C
J Nephrol; 2004; 17(6):762-8. PubMed ID: 15593048
[TBL] [Abstract][Full Text] [Related]
28. The role and value of sirolimus administration in kidney and liver transplantation.
Mehrabi A; Fonouni H; Kashfi A; Schmied BM; Morath Ch; Sadeghi M; Schemmer P; Encke J; Sauer P; Zeier M; Weitz J; Büchler MW; Schmidt J
Clin Transplant; 2006; 20 Suppl 17():30-43. PubMed ID: 17100699
[TBL] [Abstract][Full Text] [Related]
29. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
Eisen H; Kobashigawa J; Starling RC; Valantine H; Mancini D
Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
[TBL] [Abstract][Full Text] [Related]
30. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
31. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
[TBL] [Abstract][Full Text] [Related]
32. [The role of some selected risk factors in the development of the nephrotoxicity of immunosuppressive medications used after the heart transplantation in children and young adults].
Hyla-Klekot L; Kucharska G
Przegl Lek; 2006; 63 Suppl 3():40-3. PubMed ID: 16898485
[TBL] [Abstract][Full Text] [Related]
33. [Minimizing the risk of cancer in transplant patients].
Campistol JM
G Ital Nefrol; 2010; 27 Suppl 50():S81-5. PubMed ID: 20922701
[TBL] [Abstract][Full Text] [Related]
34. [Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].
Infante B; Stallone G; Schena A; Maiorano A; Gesualdo L; Schena FP; Grandaliano G
G Ital Nefrol; 2006; 23(4):389-95. PubMed ID: 17063439
[TBL] [Abstract][Full Text] [Related]
35. Fighting malignancy in organ transplant recipients.
Geissler EK
Transplant Proc; 2009; 41(6 Suppl):S9-12. PubMed ID: 19651298
[TBL] [Abstract][Full Text] [Related]
36. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
Cruzado JM
Transplant Rev (Orlando); 2008 Jan; 22(1):73-81. PubMed ID: 18631860
[TBL] [Abstract][Full Text] [Related]
37. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Nashan B
Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
[TBL] [Abstract][Full Text] [Related]
38. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.
Marcén R; Galeano C; Fernández-Rodriguez A; Jiménez-Alvaro S; Teruel JL; Rivera M; Burgos FJ; Quereda C
Transplant Proc; 2010 Oct; 42(8):3055-7. PubMed ID: 20970609
[TBL] [Abstract][Full Text] [Related]
39. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
Alamo JM; Barrera L; Casado MD; Bernal C; Marin LM; Suarez G; Sanchez-Moreno L; Jimenez R; Suarez-Grau JM; Sousa JM; Cordero E; Gomez-Bravo MA
Transplant Proc; 2009; 41(6):2181-3. PubMed ID: 19715866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]